The metabolism of antipyrine was studied in 13 patients with cancer and bladder papillomas and in 11 control subjects, matched for interfering factors like smoking, diet, age and sex. The mean antipyrine half-life was significantly longer in patients with urinary tract cancer (14.7 ± 1.32 h SE) than in control subjects (11 ± 0.55 h SE) (P < 0.025); other clinical parameters did not vary.
Get full access to this article
View all access options for this article.
References
1.
AmbreJ., ButesF., HauptD., GraffD., DeasonK.: Antipyrine metabolism in patients with lung cancer.Clin. Res., 22: 598A, 1974.
2.
BrodieB.B., AxelrodJ., SobermanR., LevyB.B.: The estimation of antipyrine in biological materials.J. Biol. Chem., 179: 25–29, 1949.
3.
HiguchiT., NakamuraT., UchinoH.: Antipyrine metabolism in cancer patients.Cancer, 45: 541–544, 1980.
4.
KatoR., TakanakaA., OshimaT.: Drug metabolism in tumor-bearing rats.II. Jap. J. Pharmacol., 18: 245, 1968.
5.
RossoR., DonelliM.G., FranchiG., GarattiniS.: Impairment of drug metabolism in tumor-bearing animals.Eur. J. Cancer., 7: 565, 1971.
6.
TschanzC., HigniteC.E., HuffmanD., AzarnoffD.L.: Metabolism disposition of antipyrine in patients with lung cancer.Cancer Res., 37: 3881–3886, 1977.
